As of the latest session, AMRN stock price traded around $1.16, reflecting mild upward momentum amid biotech sector volatility. Investors are eyeing Q4 earnings guidance for clues on Vascepa sales trajectory and regulatory developments. Amarin Corp PLC ( NASDAQ:AMRN ) is set to release its Q3 2024 earnings on Oct 30, 2024. The consensus estimate for Q3 2024 revenue is $44.51 million, and the earnings are expected to come in at -$0.05 per share. The full year 2024's revenue is expected to be $206.53 million and the earnings are expected to be -$0.14 per share. More detailed estimate data can be found on the Forecast page . Amarin is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, MannKind (MNKD), finished the last trading session 5.1% higher at $3.99. MNKD has returned -7.9% over the past month. AMRN stock price recently hovered near $1.18, supported by moderate volume. Analysts suggest potential near-term catalysts could include expanded cardiovascular indications and litigation outcomes impacting market sentiment.